Rationale for azithromycin in COVID-19: an overview of existing evidence

Azithromycin has rapidly been adopted as a repurposed drug for the treatment of COVID-19, despite the lack of high-quality evidence. In this review, we critically appraise the current pharmacological, preclinical and clinical data of azithromycin for treating COVID-19. Interest in azithromycin has b...

Descripción completa

Detalles Bibliográficos
Autores principales: Gyselinck, Iwein, Janssens, Wim, Verhamme, Peter, Vos, Robin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Respiratory Infection
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811960/
https://www.ncbi.nlm.nih.gov/pubmed/33441373
http://dx.doi.org/10.1136/bmjresp-2020-000806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811960/
https://www.ncbi.nlm.nih.gov/pubmed/33441373
http://dx.doi.org/10.1136/bmjresp-2020-000806

Ejemplares similares